(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2008 (25.09.2008)

PCT

(10) International Publication Number
WO 2008/113834 A3

(51) International Patent Classification:
C07K 7/00 (2006.01)

(21) International Application Number:
PCT/EP2008/053321

(22) International Filing Date: 19 March 2008 (19.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/896,408 22 March 2007 (22.03.2007) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GUILD, Braydon Charles** [US/US]; 109 Riverdale Road, Concord, Massachusetts 01742 (US). **KEATING, Mark Taylor** [US/US]; 135 Orchard Avenue, Weston, Massachusetts 02493 (US). **MILIK, Mariusz** [US/US]; 258 Gray Street, Arlington, Massachusetts 02476 (US). **MIKHAILOV, Dmitri** [US/US]; 305G Winchester Street, Newton, Massachusetts 02461 (US). **ROGUSKA, Michael** [US/US]; 16 Hilldale Road, Ashland, Massachusetts 01721 (US). **SPLAWSKI, Igor** [PL/US]; 907 Main Street #5, Winchester, Massachusetts 01890 (US). **ZHAO, Kehao** [CN/US]; 130 Edinboro Street, Newton, Massachusetts 02460 (US).

(74) Agent: **VON SPRECHER, Georg**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
5 March 2009

(54) Title: C5 ANTIGENS AND USES THEREOF

(57) Abstract: The present invention pertains to the use of a complement component C5 inhibitor in methods of treatment of ocular disorders and the use of a complement component C5 inhibitor in the manufacture of a medicament in the treatment of an ocular disorder.

WO 2008/113834 A3